Trial Profile
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleotide/Nucleoside Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Lersivirine (Primary) ; Darunavir; Etravirine; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Pfizer; ViiV Healthcare
- 16 Dec 2021 This trial has been completed in France (End Date: 18 Oct 2012), according to European Clinical Trials Database record.
- 25 Jul 2019 This trial has been completed in United Kingdom
- 01 May 2016 This trial was completed in Italy according to the European Clinical Trials Database.